

Enabling early detection of psoriatic arthritis

Aug 21, 2024

Partnership with Clarius Mobile Health is enabling early detection of Psoriatic Arthritis

An estimated one third of the one million Canadians living with psoriasis also suffer from psoriatic arthritis (PsA).¹ Of those Canadians, more than half of patients with PsA wait at least four years, if not longer, for diagnosis. When left untreated, psoriatic arthritis can cause irreversible damage in as little as six months.^{2,3} By improving access to ultrasound technology, rheumatologists would be able to not only identify diagnostic markers sooner, but also positively impact the timeline to diagnosis for PsA patients.

Partnership leads to innovation. As part of our dedicated effort to aid in the early detection of psoriatic arthritis in Canada, a new, two-year partnership with Clarius Mobile Health was launched in May 2024 to challenge the status quo for psoriatic arthritis detection timelines. The partnership with Clarius will facilitate access to handheld ultrasound devices for rheumatologists and include training, support and ongoing education for the duration of the program.

Read more about how the partnership with Clarius will improve the patient diagnosis journey and support Canadian business from Sean Silcoff in The Globe and Mail:

[B.C. wireless ultrasound maker Clarius gets boost from deal with Swiss drug giant Novartis*](#)

Source URL: <https://prod1.novartis.com/ca-en/stories/enabling-early-detection-psoriatic-arthritis>

List of links present in page

1. <https://prod1.novartis.com/ca-en/ca-en/en/stories/enabling-early-detection-psoriatic-arthritis>
2. <https://prod1.novartis.com/ca-en/en/stories/global-impact>
3. <https://www.theglobeandmail.com/business/article-clarius-mobile-novartis-ultrasound/>